Literature DB >> 23681862

Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone.

Jason Boland1, Elaine Boland, David Brooks.   

Abstract

Opioids can induce respiratory depression by invoking a centrally mediated decrease in involuntary respiratory rate, which in severe cases can cause a decrease in oxygen saturation. If respiratory depression is opioid induced, both low respiratory rate and low oxygen saturation will be present. If this is the case, oxygenation, rousing by verbal and physical stimulation and decreasing the opioid dose should be tried first. Naloxone, an opioid antagonist, should be avoided if at all possible but, if essential, titrate slowly to respiratory function administering 20-100 µg intravenously every two minutes. If used as a bolus for a patient on long-term opioids for chronic cancer pain, then refractory pain and symptomatic opioid withdrawal can result.

Entities:  

Keywords:  cancer pain; naloxone; opioid; respiratory depression

Mesh:

Substances:

Year:  2013        PMID: 23681862      PMCID: PMC4952630          DOI: 10.7861/clinmedicine.13-2-149

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  10 in total

1.  Low-dose remifentanil infusion does not impair natural killer cell function in healthy volunteers.

Authors:  A J Cronin; N M Aucutt-Walter; T Budinetz; C P Bonafide; N A DiVittore; V Gordin; H G Schuler; R H Bonneau
Journal:  Br J Anaesth       Date:  2003-12       Impact factor: 9.166

Review 2.  Looking for inspiration: new perspectives on respiratory rhythm.

Authors:  Jack L Feldman; Christopher A Del Negro
Journal:  Nat Rev Neurosci       Date:  2006-03       Impact factor: 34.870

3.  Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects.

Authors:  Nicola Lister; Steve Warrington; Malcolm Boyce; Catarina Eriksson; Masami Tamaoka; John Kilborn
Journal:  J Clin Pharmacol       Date:  2011-01-05       Impact factor: 3.126

4.  Opioid-induced respiratory depression is associated with increased tidal volume variability.

Authors:  T Bouillon; J Bruhn; H Roepcke; A Hoeft
Journal:  Eur J Anaesthesiol       Date:  2003-02       Impact factor: 4.330

5.  Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.

Authors:  A Dahan; A Yassen; H Bijl; R Romberg; E Sarton; L Teppema; E Olofsen; M Danhof
Journal:  Br J Anaesth       Date:  2005-04-15       Impact factor: 9.166

6.  Increased tidal volume variability in children is a better marker of opioid-induced respiratory depression than decreased respiratory rate.

Authors:  Sean J Barbour; Christine A Vandebeek; J Mark Ansermino
Journal:  J Clin Monit Comput       Date:  2004-06       Impact factor: 2.502

7.  Buprenorphine induces ceiling in respiratory depression but not in analgesia.

Authors:  A Dahan; A Yassen; R Romberg; E Sarton; L Teppema; E Olofsen; M Danhof
Journal:  Br J Anaesth       Date:  2006-03-17       Impact factor: 9.166

8.  Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients.

Authors:  Katri Elina Clemens; Eberhard Klaschik
Journal:  J Pain Symptom Manage       Date:  2007-04       Impact factor: 3.612

9.  Is there a higher risk of respiratory depression in opioid-naïve palliative care patients during symptomatic therapy of dyspnea with strong opioids?

Authors:  Katri Elina Clemens; Ines Quednau; Eberhard Klaschik
Journal:  J Palliat Med       Date:  2008-03       Impact factor: 2.947

10.  Determination of the human brainstem respiratory control network and its cortical connections in vivo using functional and structural imaging.

Authors:  Kyle T S Pattinson; Georgios D Mitsis; Ann K Harvey; Saad Jbabdi; Sharon Dirckx; Stephen D Mayhew; Richard Rogers; Irene Tracey; Richard G Wise
Journal:  Neuroimage       Date:  2008-09-24       Impact factor: 6.556

  10 in total
  6 in total

1.  The balance between effective opioid-based pain management and patient safety: can it be achieved?

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2013-10

Review 2.  Updates in palliative care - overview and recent advancements in the pharmacological management of cancer pain.

Authors:  Helen Wood; Andrew Dickman; Angela Star; Jason W Boland
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

Review 3.  Influence of opioids on immune function in patients with cancer pain: from bench to bedside.

Authors:  Jason W Boland; A Graham Pockley
Journal:  Br J Pharmacol       Date:  2017-07-23       Impact factor: 8.739

4.  Mas-related G-protein-coupled receptor c agonist bovine adrenal medulla 8-22 attenuates bone cancer pain in mice.

Authors:  Yu-E Sun; Cui-E Lu; Yishan Lei; Yue Liu; Zhengliang Ma; Xiaoping Gu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

5.  Mas-Related Gene (Mrg) C Activation Attenuates Bone Cancer Pain via Modulating Gi and NR2B.

Authors:  Yu'e Sun; Ming Jiang; Bailing Hou; Cui'e Lu; Yishan Lei; Zhengliang Ma; Xiaoping Gu
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

6.  Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial.

Authors:  Lynn R Webster; Jacqueline Cater; Thomas Smith
Journal:  Pain Ther       Date:  2022-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.